【横河电机株式会社】2024智能制造评估引领制药制造商迈向智能工厂的数字化转型之路白皮书_12页_3mb

SMART MANUFACTURING Assessment Summary

Core Content

The document outlines the challenges and opportunities facing pharmaceutical manufacturers in the context of digital transformation (DX) and Smart Manufacturing (SM). It emphasizes the need for pharmaceutical companies to adapt to evolving market demands, regulatory pressures, and technological advancements to remain competitive and deliver high-quality medicines efficiently. The transition to Industry 4.0 is presented as a strategic imperative, with Yokogawa positioned as a trusted partner in guiding this transformation through a structured, value-driven approach.

Main Points and Key Information

Industry Challenges and Trends

• Rapid Changes: The pharmaceutical industry faces increasing demands due to population growth, aging populations, and new therapeutic modalities.
• Regulatory Pressures: Companies must comply with strict regulations and ensure the safety, efficacy, and quality of medicines.
• New Modalities: Antibody drugs, nucleic acid and peptide drugs, and cell therapy are becoming more prevalent, requiring new production capabilities.
• Cost and Productivity: Balancing cost optimization with productivity and stable supply is essential.
• Digital Transformation (DX): DX is seen as a means to achieve these goals, but it requires careful planning and execution.

Pharma 4.0 and Industry 4.0

• Pharma 4.0: A roadmap for the pharmaceutical industry to implement Industry 4.0 technologies, focusing on IT integration and operational efficiency.
• IT/OT Convergence: Critical for aligning digital transformation with existing regulatory frameworks and operational models.

Yokogawa's Role in DX

• Smart Manufacturing Assessment (SM Assessment): A three-step methodology to guide companies in identifying digital priorities, assessing maturity, and developing a customized roadmap.
• TIER Framework: Used to prioritize DX initiatives based on four dimensions: T (Assessment Matrix Score), I (Cost Profile), E (Key Performance Indicators), and R (Best-in-Class Benchmark).
• S.I.R.I. Index: A global digital maturity index developed by Singapore EDB, used to evaluate and compare a company's readiness for Industry 4.0 transformation.
• Certified S.I.R.I. Assessors (CSAs): Yokogawa's trained professionals evaluate companies across Process, Technology, and Organization building blocks.
• Comprehensive Solutions: Yokogawa offers a wide range of digital enterprise solutions, including ERP systems, production management, quality control, and IT/OT convergence tools.

Digital Transformation Roadmap

• A phased approach is recommended to align with national regulatory requirements and industry standards (e.g., PIC/S, ICH).
• The roadmap includes short-term wins and long-term goals, tailored to each company's specific needs and objectives.
• The aim is to create a system of systems (SoS), where interconnected components work together to achieve greater autonomy and efficiency.

Smart Manufacturing Benefits

• In-plant: Enhances quality and reduces costs while increasing manufacturing efficiency.
• Company-wide: Optimizes the entire production process from a strategic management perspective.
• Supply Chain: Improves information consistency across the supply chain, reducing losses and lead times.
• Societal Impact: Encourages collaboration across industries and regions to solve broader social issues.

Key Functional Areas

Industry 4.0 Maturity and Vision

• Digital Maturity Levels: Companies vary in their readiness for digital transformation, and a widening gap is expected between early adopters and laggards.
• Importance of Early Action: Starting early with DX initiatives is crucial to secure a strong position in the industry and adapt to future trends.
• Future of Manufacturing: Yokogawa envisions a future of Bio Industrial Autonomy (BIA), where production systems operate autonomously, reducing human intervention and increasing efficiency.

Customer Feedback and Yokogawa's Commitment

• Yokogawa has been a valuable partner in the digitalization journey of pharmaceutical manufacturers, providing relevant workshops and solutions.
• Customers emphasize the importance of systematic support and expertise in achieving smart manufacturing goals.
• Yokogawa's mission is to create a better future through collaboration, innovation, and the development of smart factories.

Conclusion

The document highlights the critical need for pharmaceutical manufacturers to embrace digital transformation to meet the challenges of a rapidly evolving industry. Yokogawa offers a structured, value-led approach to SM assessment and implementation, leveraging the S.I.R.I. index and the TIER framework to guide companies toward a successful and sustainable Industry 4.0 transformation.